These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
137 related items for PubMed ID: 11752062
1. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, Brady RO, Sokoloff L, Moore DF. J Neurochem; 2001 Dec; 79(6):1217-24. PubMed ID: 11752062 [Abstract] [Full Text] [Related]
2. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease. Sueoka H, Aoki M, Tsukimura T, Togawa T, Sakuraba H. PLoS One; 2015 Dec; 10(12):e0144958. PubMed ID: 26661087 [Abstract] [Full Text] [Related]
3. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. Bangari DS, Ashe KM, Desnick RJ, Maloney C, Lydon J, Piepenhagen P, Budman E, Leonard JP, Cheng SH, Marshall J, Thurberg BL. Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976 [Abstract] [Full Text] [Related]
4. Altered globotriaosylceramide accumulation and mucosal neuronal fiber density in the colon of the Fabry disease mouse model. Masotti M, Delprete C, Dothel G, Donadio V, Rimondini R, Politei JM, Liguori R, Caprini M. Neurogastroenterol Motil; 2019 Mar; 31(3):e13529. PubMed ID: 30609268 [Abstract] [Full Text] [Related]
5. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, Sá-Miranda MC. Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893 [Abstract] [Full Text] [Related]
6. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Taguchi A, Maruyama H, Nameta M, Yamamoto T, Matsuda J, Kulkarni AB, Yoshioka H, Ishii S. Biochem J; 2013 Dec 15; 456(3):373-83. PubMed ID: 24094090 [Abstract] [Full Text] [Related]
7. An in vitro model of Fabry disease. Shu L, Murphy HS, Cooling L, Shayman JA. J Am Soc Nephrol; 2005 Sep 15; 16(9):2636-45. PubMed ID: 16033856 [Abstract] [Full Text] [Related]
8. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Park J, Murray GJ, Limaye A, Quirk JM, Gelderman MP, Brady RO, Qasba P. Proc Natl Acad Sci U S A; 2003 Mar 18; 100(6):3450-4. PubMed ID: 12624185 [Abstract] [Full Text] [Related]
14. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model. Park ES, Choi JO, Park JW, Lee MH, Park HY, Jung SC. Int J Mol Med; 2009 Sep 18; 24(3):401-7. PubMed ID: 19639234 [Abstract] [Full Text] [Related]
19. Characterization of small fiber pathology in a mouse model of Fabry disease. Hofmann L, Hose D, Grießhammer A, Blum R, Döring F, Dib-Hajj S, Waxman S, Sommer C, Wischmeyer E, Üçeyler N. Elife; 2018 Oct 17; 7():. PubMed ID: 30328411 [Abstract] [Full Text] [Related]
20. Genetics and Gene Therapy of Anderson-Fabry Disease. Simonetta I, Tuttolomondo A, Di Chiara T, Miceli S, Vogiatzis D, Corpora F, Pinto A. Curr Gene Ther; 2018 Oct 17; 18(2):96-106. PubMed ID: 29618309 [Abstract] [Full Text] [Related] Page: [Next] [New Search]